A Phase 3 interventional study of Metformin and Insulin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 83 sites in 14 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-02-23.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment, is the only one that started in 2018, is one of 31 in phase 3, and was the 58th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Bahria University · Sites in Pakistan
Ages 30–55
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 175 across the 67 interventional studies. Of the 60 that completed or were terminated, 41 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 62nd largest by enrollment of the 96 interventional ones that give a count, is one of 5 that started in 2018, is one of 50 in phase 3, and was the 107th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking metformin, insulin or both drugs (DINAMO TM) or who are treatment naïve or not on active treatment after metformin withdrawal (DINAMO TM MONO) .
Empagliflozin and linagliptin are both approved for use in adult patients with type 2 diabetes. This study will assess how well empagliflozin and linagliptin work by finding out how these treatments affect blood glucose (sugar) levels compared to placebo (a pill that contains no active drug), in children and adolescents. Empagliflozin and linagliptin are considered investigational products in this study since while they have been approved for use in adults, they have not been approved for children and adolescents due to lack of clinical studies in this specific population.
Patients with type 2 diabetes have higher levels of blood glucose (sugar) than patients who do not have this disease. The high level of sugar in the blood can lead to serious short-term and long-term medical problems. The main goal of treating diabetic patients is to lower blood glucose to a normal level. Lowering and controlling blood glucose help prevent or delay complications of diabetes such as heart disease, kidney, eye and nerve diseases, and the possibility of amputation.
Empagliflozin is a drug that helps to reduce blood glucose (sugar) levels by causing glucose to be excreted in the urines.
Linagliptin works by increasing the production of insulin (a hormone that controls the level of blood glucose) after meals when blood glucose (sugar) levels are too high. This helps to lower blood sugar levels.
The subject will either receive one of the active study drugs or a placebo. This study will be double blind; this means that neither the subject, nor the study doctor will know which treatment the subject will receive.
Which treatment the subject receives is decided by a computer, purely by chance; this is called a "random assignment".
For this study, there will first be a screening visit, followed by a 2-week placebo run-in period (all subjects will take placebo once daily). This run-in period is designed to ensure subjects are able to take the study drugs as described in the study protocol. Thereafter there will be a 26-week treatment phase (week 1-week 26) and a 26-week safety extension period (week 27-week 52). Following this there will be a follow-up visit at week 55.
On Day 1 after the placebo run-in phase, the subject will be randomly assigned to receive one of the 3 treatments: empagliflozin 10 mg, linagliptin 5 mg or placebo in a blinded manner. This treatment will continue up to week 14. Then after week 14, the subject will be assigned to receive one of the following 4 treatments: empagliflozin 10 mg, empagliflozin 25 mg, linagliptin 5 mg or placebo in a blinded manner. The drugs assigned after week 14 will be the same drugs as on Day 1 but some subjects will receive a higher dose of empagliflozin.
After the completion of the 26-week treatment period, the subject will enter a 26-week safety extension period. The same active treatment that the subject had been assigned to at week 14 visit will be continued. Subjects assigned to placebo on Day 1 will be randomly assigned to receive one of the 3 active treatments: empagliflozin 10 mg, empagliflozin 25 mg or linagliptin 5 mg in a blinded manner. This safety extension period is primarily designed to provide additional information on how well empagliflozin and linagliptin are tolerated.
Following the treatment phases, there will be a follow-up visit at week 55
Intervention model description:
Eligible subjects with HbA1c of 6.5% to 10.5% at screening will be randomized in a 1:1:1 ratio to receive empagliflozin 10 mg, linagliptin 5 mg or placebo. HbA1c assessment will be performed at Week 12. All subjects with Week 12 HbA1c \< 7% will remain on previously assigned randomized treatment. Subjects taking empagliflozin with Week 12 HbA1c >= 7% will be re-randomized in a 1:1 ratio to continue on the low dose treatment (empagliflozin 10 mg) or up-titrate to the high dose treatment (empagliflozin 25 mg). Subjects taking linagliptin or placebo with Week 12 HbA1c >= 7% will remain on previously assigned treatment. All subjects will get new medication kits dispensed at Week 14 to maintain the blinding.
At Week 26, all subjects previously assigned to placebo will be re-randomized in a 1:1:1: ratio to receive one of the active treatments: empagliflozin 10 mg, empagliflozin 25 mg or linagliptin 5 mg. All subjects will get new medication kits dispensed at Week 14 to maintain the blinding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented diagnosis of T2DM at Visit 1A:
Insufficient glycaemic control as measured by the central laboratory at Visit 1A:
DINAMO TM: Patients treated with
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.
Drug: Metformin · Drug: Insulin · Drug: Placebo
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.
Drug: Metformin · Drug: Insulin · Drug: Placebo · Drug: Linagliptin
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 10 milligram (mg) empagliflozin, taken once daily, until end of treatment.
Drug: Metformin · Drug: Insulin · Drug: Placebo · Drug: Empagliflozin
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 25 milligram (mg) empagliflozin, taken once daily, until end of treatment.
Drug: Metformin · Drug: Insulin · Drug: Placebo · Drug: Empagliflozin
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 5 milligram (mg) Linagliptin once daily, until end of treatment.
Drug: Metformin · Drug: Insulin · Drug: Linagliptin
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily, until Week 14. Responder patients were not re-randomised at week 14 and continued 10 mg empagliflozin, taken once daily, until end of treatment. Non responder patients were re-randomised at Week 14 to receive 10 mg empagliflozin, taken once daily, until end of treatment.
Drug: Metformin · Drug: Insulin · Drug: Empagliflozin
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily until Week 14. Non responder patients were re-randomised at Week 14 to receive 25 mg empagliflozin, taken once daily, until end of treatment.
Drug: Metformin · Drug: Insulin · Drug: Empagliflozin
At least 1000 mg/day or up to a maximal tolerated dose.
Basal or multiple dose injection.
1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.
1 film-coated tablet Linagliptin once daily, until end of treatment.
Also known as: Trajenta(R)
1 film-coated tablet of Empagliflozin once daily, until end of treatment.
Also known as: Jardiance(R)
Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ
Adjusted means taken from the following three models, as pre-specified in the protocol: Treatment group 1 (TG1): \[Placebo\], \[Linagliptin 5mg\] and \[Empagliflozin pooled\] Treatment group 2 (TG2): \[Placebo\] and \[Empagliflozin 10mg and 10+25mg\] Treatment group 3 (TG3): \[Placebo\] and \[Empagliflozin 10mg\] ANCOVA with continuous covariate (baseline HbA1c) and categorical covariates (treatment \& age). Effect of linagliptin and of empagliflozin was compared with placebo at an overall α of 0.05 (2-sided) using the Hochberg method to account for multiple testing. After having obtained statistically significant results for both hypotheses of the primary family of hypotheses (TG1), the secondary hypotheses were to compare the individual empagliflozin doses versus placebo (TG2 \& TG3). ANCOVA utilized a weight of zero for patients who were not in the hypothesis test of interest, a value of 2 for re-randomised patients who were in the hypothesis test of interest and a value of 1 otherwise.
Time frame: Baseline (Day 1) and week 26 of treatment.
Percentage of Patients With Treatment Failure up to or at Week 26
Percentage of patients with treatment failure up to or at Week 26 as a binary endpoint, defined as meeting at least one of the following criteria: * Use of rescue medication at any time up to Week 26 * Increase from baseline in HbA1c by 0.5% at Week 26 . Increase from baseline in HbA1c to above 7.0% at Week 26 in patients with baseline HbA1c \<7.0%
Time frame: Up to 26 weeks.
Change in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono
Change in Glycated haemoglobin (HbA1c) (%) from baseline to the end of 26 weeks. Adjusted values came from a restricted maximum likelihood (REML) approach with mixed model for repeated measures (MMRM). Analyses included fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as the repeated measure with an unstructured covariance structure used to model the within-patient measurements.
Time frame: Baseline (Day 1) and week 26 of treatment.
Time to Treatment Failure
Time to treatment failure was analysed by Kaplan-Meier estimates up to the end of the study (Week 52). Patients in the placebo group were censored after 26 weeks unless a prior treatment failure was observed.
Time frame: Up to 395 days.
Change in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks
Change in fasting plasma glucose (FPG, Milligrams Per Deciliter (mg/dL)) from baseline to the end of 26 weeks. Adjusted values taken from analysis of covariance (ANCOVA) model with treatment as a fixed classification effect, baseline FPG as linear covariate and age at randomisation as categorical covariate. The random error was assumed to be normally distributed.
Time frame: Baseline (Day 1) and week 26.
Change in Body Weight (kg) From Baseline to the End of 26 Weeks
Change in body weight (kg) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.
Time frame: Baseline (Day 1) and week 26.
Change in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks
Change in systolic blood pressure (SBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.
Time frame: Baseline (Day 1) and week 26.
Change in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks
Change in diastolic blood pressure (DBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.
Time frame: Baseline (Day 1) and week 26.
Percentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks
Percentage of patients who achieve HbA1c \<6.5% at the end of 26 weeks.
Time frame: Baseline (Day 1) and week 26.
Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks
Percentage of patients who achieve HbA1c \<7.0% at the end of 26 weeks.
Time frame: Baseline (Day 1) and week 26.
This study was a randomised, placebo-controlled, double-blind, and parallel group trial with 3 treatment arms (placebo, 5 mg linagliptin, 10 mg empagliflozin). The main trial DINAMOᵀᴹ consisted of patients treated with metformin and/or insulin or patients who do not tolerate metformin. The ancillary trial DINAMOᵀᴹ Mono consisted of treatment-naïve patients or patients not on active treatment.
| Milestone | Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono |
|---|---|---|---|---|---|---|---|
| Started | 7 | 19 | 16 | 16 | 59 | 45 | 13 |
| Treated | 7 | 19 | 16 | 16 | 58 | 45 | 13 |
| Completed | 0 | 17 | 15 | 14 | 47 | 36 | 12 |
| Not completed | 7 | 2 | 1 | 2 | 12 | 9 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 1 | 2 | 6 | 3 | 1 |
| Withdrew: Other reason than listed | 0 | 1 | 0 | 0 | 4 | 4 | 0 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Adjusted means taken from the following three models, as pre-specified in the protocol: Treatment group 1 (TG1): \[Placebo\], \[Linagliptin 5mg\] and \[Empagliflozin pooled\] Treatment group 2 (TG2): \[Placebo\] and \[Empagliflozin 10mg and 10+25mg\] Treatment group 3 (TG3): \[Placebo\] and \[Empagliflozin 10mg\] ANCOVA with continuous covariate (baseline HbA1c) and categorical covariates (treatment \& age). Effect of linagliptin and of empagliflozin was compared with placebo at an overall α of 0.05 (2-sided) using the Hochberg method to account for multiple testing. After having obtained statistically significant results for both hypotheses of the primary family of hypotheses (TG1), the secondary hypotheses were to compare the individual empagliflozin doses versus placebo (TG2 \& TG3). ANCOVA utilized a weight of zero for patients who were not in the hypothesis test of interest, a value of 2 for re-randomised patients who were in the hypothesis test of interest and a value of 1 otherwise.
| Percent change | Placebo - DINAMOᵀᴹ (TG1, TG2 & TG3) | Linagliptin 5 mg - DINAMOᵀᴹ (TG1) | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ (TG1) | Empagliflozin 10 mg - DINAMOᵀᴹ (TG3) | Empagliflozin 10 mg - DINAMOᵀᴹ & Empagliflozin 10 - 25 mg - DINAMOᵀᴹ (TG2) |
|---|---|---|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ | NA (NA to NA) | 0.33 (-0.13 to 0.79) | -0.17 (-0.64 to 0.31) | -0.49 (-1.03 to 0.04) | 0.14 (-0.42 to 0.71) |
Percentage of patients with treatment failure up to or at Week 26 as a binary endpoint, defined as meeting at least one of the following criteria: * Use of rescue medication at any time up to Week 26 * Increase from baseline in HbA1c by 0.5% at Week 26 . Increase from baseline in HbA1c to above 7.0% at Week 26 in patients with baseline HbA1c \<7.0%
| Percentage of subjects | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|
| Percentage of Patients With Treatment Failure up to or at Week 26 | 60.0 (18.9 to 92.4) | 50.0 (15.3 to 84.7) | 50.0 (15.3 to 84.7) |
Change in Glycated haemoglobin (HbA1c) (%) from baseline to the end of 26 weeks. Adjusted values came from a restricted maximum likelihood (REML) approach with mixed model for repeated measures (MMRM). Analyses included fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as the repeated measure with an unstructured covariance structure used to model the within-patient measurements.
| Percent change | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|
| Change in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono | 0.15 (-1.45 to 1.75) | -0.53 (-2.01 to 0.95) | -0.23 (-1.83 to 1.37) |
Time to treatment failure was analysed by Kaplan-Meier estimates up to the end of the study (Week 52). Patients in the placebo group were censored after 26 weeks unless a prior treatment failure was observed.
| Days | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|
| Time to Treatment Failure | 65.600 ± 19.941 | 72.167 ± 20.280 | 167.333 ± 26.711 |
Change in fasting plasma glucose (FPG, Milligrams Per Deciliter (mg/dL)) from baseline to the end of 26 weeks. Adjusted values taken from analysis of covariance (ANCOVA) model with treatment as a fixed classification effect, baseline FPG as linear covariate and age at randomisation as categorical covariate. The random error was assumed to be normally distributed.
| Milligrams Per Deciliter (mg/dL) | Placebo - DINAMOᵀᴹ | Linagliptin 5 mg - DINAMOᵀᴹ | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks | 15.70 (-0.53 to 31.93) | 10.29 (-6.12 to 26.69) | -19.48 (-36.39 to -2.57) | -38.50 (-62.67 to -14.33) | 0.12 (-23.67 to 23.91) | -18.45 (-40.00 to 3.10) |
Change in body weight (kg) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.
| kilogram (kg) | Placebo - DINAMOᵀᴹ | Linagliptin 5 mg - DINAMOᵀᴹ | Empagliflozin Pooled (10 mg and 25 mg) | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|---|---|---|
| Change in Body Weight (kg) From Baseline to the End of 26 Weeks | -0.04 (-1.40 to 1.32) | 1.42 (0.04 to 2.81) | -0.79 (-2.17 to 0.59) | 2.64 (-0.35 to 5.63) | 2.69 (0.24 to 5.14) | 1.29 (-1.75 to 4.33) |
Change in systolic blood pressure (SBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.
| millimeters of mercury (mmHg) | Placebo - DINAMOᵀᴹ | Linagliptin 5 mg - DINAMOᵀᴹ | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|---|---|---|
| Change in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks | 1.30 (-1.01 to 3.61) | 2.21 (-0.14 to 4.56) | -0.12 (-2.47 to 2.24) | 2.63 (-4.07 to 9.34) | 5.16 (-0.74 to 11.06) | 2.63 (-4.86 to 10.12) |
Change in diastolic blood pressure (DBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.
| millimeters of mercury (mmHg) | Placebo - DINAMOᵀᴹ | Linagliptin 5 mg - DINAMOᵀᴹ | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|---|---|---|
| Change in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks | 0.76 (-1.01 to 2.53) | 2.26 (0.46 to 4.05) | 0.78 (-1.04 to 2.60) | 3.42 (-4.92 to 11.75) | 6.75 (0.14 to 13.35) | -3.20 (-10.10 to 3.69) |
Percentage of patients who achieve HbA1c \<6.5% at the end of 26 weeks.
| Percentage of subjects | Placebo - DINAMOᵀᴹ | Linagliptin 5 mg - DINAMOᵀᴹ | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|---|---|---|
| Percentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks | 9.4 | 15.4 | 21.2 | 40.0 | 16.7 | 16.7 |
Percentage of patients who achieve HbA1c \<7.0% at the end of 26 weeks.
| Percentage of subjects | Placebo - DINAMOᵀᴹ | Linagliptin 5 mg - DINAMOᵀᴹ | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ | Placebo - DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ Mono | Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono |
|---|---|---|---|---|---|---|
| Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks | 24.5 | 26.9 | 34.6 | 40.0 | 16.7 | 66.7 |
Collected over Date of first study drug intake until date of last active study drug intake + residual effect period (7 days), up to 402 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | 0/58 (0%) | 2/58 (3.4%) | 30/58 (51.7%) |
| Linagliptin 5 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | 0/77 (0%) | 8/77 (10.4%) | 45/77 (58.4%) |
| Empagliflozin 10 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | 0/74 (0%) | 4/74 (5.4%) | 47/74 (63.5%) |
| Empagliflozin 25 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | 0/29 (0%) | 0/29 (0%) | 14/29 (48.3%) |
| Event | Placebo Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 25 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono |
|---|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/58 | 2/77 | 0/74 | 0/29 |
| Splenic vein thrombosisBlood and lymphatic system disorders | 1/58 | 0/77 | 0/74 | 0/29 |
| Pancreatitis acuteGastrointestinal disorders | 1/58 | 0/77 | 0/74 | 0/29 |
| Systemic inflammatory response syndromeGeneral disorders | 1/58 | 0/77 | 0/74 | 0/29 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/58 | 1/77 | 0/74 | 0/29 |
| Acute kidney injuryRenal and urinary disorders | 1/58 | 0/77 | 0/74 | 0/29 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/58 | 0/77 | 0/74 | 0/29 |
| Hypovolaemic shockVascular disorders | 1/58 | 0/77 | 0/74 | 0/29 |
| ColitisGastrointestinal disorders | 0/58 | 0/77 | 1/74 | 0/29 |
| Skin candidaInfections and infestations | 0/58 | 0/77 | 1/74 | 0/29 |
| Event | Placebo Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 25 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 7/58 | 16/77 | 12/74 | 5/29 |
| HeadacheNervous system disorders | 9/58 | 12/77 | 12/74 | 3/29 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 8/58 | 6/77 | 10/74 | 2/29 |
| VomitingGastrointestinal disorders | 2/58 | 8/77 | 5/74 | 2/29 |
| Blood ketone body increasedInvestigations | 2/58 | 8/77 | 5/74 | 3/29 |
| DiarrhoeaGastrointestinal disorders | 5/58 | 7/77 | 3/74 | 2/29 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/58 | 6/77 | 4/74 | 1/29 |
| DysmenorrhoeaReproductive system and breast disorders | 0/58 | 2/77 | 6/74 | 1/29 |
| NasopharyngitisInfections and infestations | 3/58 | 6/77 | 3/74 | 1/29 |
| Abdominal painGastrointestinal disorders | 4/58 | 5/77 | 4/74 | 1/29 |
The randomised set (RS) included all randomised patients, regardless whether they took trial medication
| Age, Continuous(years) | Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 15.3 ± 1.4 | 14.3 ± 1.7 | 14.1 ± 2.2 | 14.8 ± 1.8 | 14.4 ± 2.1 | 14.6 ± 1.8 | 13.9 ± 2.2 | 14.4 ± 1.9 |
| Sex: Female, Male(Participants) | Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 6 | 12 | 11 | 8 | 36 | 31 | 8 | 112 |
| Male | 1 | 7 | 5 | 8 | 23 | 14 | 5 | 63 |
| Ethnicity (NIH/OMB)(Participants) | Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 10 | 5 | 7 | 24 | 12 | 6 | 65 |
| Not Hispanic or Latino | 6 | 9 | 11 | 9 | 35 | 33 | 7 | 110 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian/Alaska Native | 0 | 1 | 0 | 0 | 3 | 4 | 0 | 8 |
| Asian | 0 | 1 | 1 | 1 | 5 | 2 | 0 | 10 |
| Black/African American | 5 | 4 | 3 | 6 | 17 | 20 | 4 | 59 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 3 |
| White | 1 | 13 | 10 | 9 | 28 | 17 | 7 | 85 |
| Other including mixed or missing race | 1 | 0 | 1 | 0 | 4 | 2 | 2 | 10 |
| HbA1c(percentage) | Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 7.40 ± 0.77 | 8.01 ± 1.42 | 8.00 ± 1.28 | 8.14 ± 1.17 | 7.98 ± 1.09 | 7.78 ± 1.33 | 8.24 ± 1.08 | 7.94 ± 1.20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Mar 2018 to primary completion in Oct 2022, 54 months.
Results were first posted in Feb 2024, 1 year 4 months after primary completion. A results delay was requested in Oct 2023.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 54 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linagliptin · Empagliflozin